Table 2 Donor and transplant specific characteristics.
Year of transplantation | 1989–2019 | 1989–2000 | 2001–2010 | 2011–2019 |
|---|---|---|---|---|
Total n (%) | 220 (100%) | 36 (16.4%) | 108 (49.1%) | 76 (34.5%) |
Conditioning therapy* | ||||
unmodified MAC, n (%) | 92 (41.8%) | 31 (86.1%) | 35 (32.4%) | 26 (34.2%) |
RTC MAC, n (%) | 125 (56.8%) | 5 (13.9%) | 73 (67.6%) | 47 (61.8%) |
RIC, n (%) | 3 (1.4%) | 0 (0%) | 0 (0%) | 3 (4.0%) |
GvHD prophylaxys | ||||
CsA + Alemtuzumab, n (%) | 79 (35.9%) | 0 (0%) | 63 (58.3%) | 16 (21.1%) |
CsA + ATG, n (%) | 73 (33.2%) | 13 (36.1%) | 24 (22.2%) | 36 (47.4%) |
Others**, n (%) | 68 (30.9%) | 23 (63.9%) | 21 (19.4%) | 24 (31.6%) |
Incidence of GvHD | ||||
aGvHD, n (%) | 122 (55.5%) | 17 (47.2%) | 60 (55.6%) | 45 (59.2%) |
cGvHD, n (%) | 66 (30%) | 14 (38.9%) | 34 (31.5%) | 18 (23.7%) |
cGvHD n.a., n (%) | 52 (23.6%) | 15 (41.7%) | 18 (16.7%) | 19 (25.0%) |
Immunosuppression free survival (years), median (range) | 0.2 (0–20.9) | 0.1 (0–20.9) | 0.7 (0–17.2) | 0.1 (0–7.1) |
Donor match | ||||
MRD, n (%) | 77 (35%) | 19 (52.8%) | 34 (31.5%) | 24 (31.6%) |
MUD, n (%) | 97 (44.1%) | 12 (33.3%) | 49 (45.4%) | 36 (47.4%) |
MMRD, n (%) | 2 (1%) | 1 (2.8%) | 1 (0.9%) | 0 (0%) |
MMUD, n (%) | 44 (20%) | 4 (11.1%) | 24 (22.2%) | 16 (21.1%) |
Donor sex | ||||
Female, n (%) | 100 (45.5%) | 17 (47.2%) | 47 (43.5%) | 36 (47.4%) |
Donor recipient sex match | ||||
Matched, n (%) | 128 (58.2%) | 23 (63.9%) | 67 (62%) | 38 (50%) |
Male recipient, female donor, n (%) | 50 (22.7%) | 8 (22.2%) | 22 (20.4%) | 20 (26.3%) |
Female recipient, male donor, n (%) | 42 (19.1%) | 5 (13.9%) | 19 (17.6%) | 18 (23.7%) |
Donor age (years), median (range) | 38 (14–74) | 36 (21–59) | 40 (14–74) | 34 (19–69) |
Unknown, n (%) | 12 (5.5%) | 10 (27.8%) | 2 (1.9%) | 0 (0%) |
≤ 25 years, n (%) | 30 (13.6%) | 3 (8.3%) | 12 (11.1%) | 15 (19.7%) |
26–50 years, n (%) | 143 (65%) | 20 (55.6%) | 74 (68.5%) | 49 (64.5%) |
≥ 51 years, n (%) | 35 (15.9%) | 3 (8.3%) | 20 (18.5%) | 12 (15.8%) |
CMV risk constellation | ||||
Positive recipient, negative donor, n (%) | 52 (23.6%) | 9 (25%) | 30 (27.8%) | 13 (17.1%) |
Negative recipient, positive donor, n (%) | 22 (10%) | 2 (5.6 %) | 11 (10.2 %) | 9 (11.8%) |
Both positive, n (%) | 82 (37.3%) | 6 (16.7%) | 46 (42.6%) | 30 (39.5%) |
Both negative, n (%) | 62 (28.2%) | 17 (47.2%) | 21 (19.4%) | 24 (31.6%) |
Unknown, n (%) | 2 (0.9%) | 2 (5.6%) | 0 (0%) | 0 (0%) |
Graft source | ||||
BM, n (%) | 18 (8.2%) | 15 (41.7%) | 2 (1.9%) | 1 (1.3%) |
PBSC, n (%) | 202 (91.8%) | 21 (58.3%) | 106 (98.1%) | 75 (98.7%) |
Median CD34+ count | ||||
CD34+ cells*10^6/kg bw (range) | 6.6 (0.7–34) | 5.3 (2.5–14) | 6.6 (1.1–34) | 6.7 (0.7–17) |
Unknown graft size, n (%) | 18 (8.2%) | 18 (50%) | 0 (0%) | 0 (0%) |
